Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07589634 | A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma | PHASE2 | NOT YET_RECRUITING | 230 | — | — | Jul 20, 2026 | Nov 8, 2030 | May 15, 2026 | - | — |
Percentage of participants alive and free of treatment-emergent ASTCT Grade \>=2 CRS without the use of intervening treatment for CRS of any grade by the end of Day 28 from ramantamig dose will be reported.
| Arm | Type | Description |
|---|---|---|
| Arm A: Tocilizumab + Ramantamig | EXPERIMENTAL | Participants will receive tocilizumab alongwith ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until progressive disease (PD) or intolerable toxicity (whichever is earlier). |
| Arm B: Placebo + Ramantamig | PLACEBO_COMPARATOR | Participants will receive placebo (saline) alongwith ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until PD or intolerable toxicity (whichever is earlier). |
| Name | Type | Description |
|---|---|---|
| Ramantamig | DRUG | Ramantamig will be administered as subcutaneous (SC) injection. |
| Tocilizumab | DRUG | Tocilizumab will be administered as intravenous (IV) injection. |
| Placebo | DRUG | Placebo (saline) will be administered as IV injection. |
Inclusion criteria: * Documented diagnosis of multiple myeloma (MM) as defined by the criteria: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria; b. Measurable disease at screening as assessed by local laboratory as defined in the protocol * Received a...